文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

益生菌可能通过恢复肠道微生物群落结构和改善肠道内毒素血症来延缓非酒精性脂肪性肝病的进展。

Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.

机构信息

Department of Laboratory, The Second Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.

Department of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China.

出版信息

Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176.


DOI:10.1038/srep45176
PMID:28349964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5368635/
Abstract

Gut-derived bacterial lipopolysaccharide (LPS) and subsequent hepatic toll-like receptor 4 (TLR4) activation have been recognized to be involved in the onset of diet-induced nonalcoholic fatty liver disease (NAFLD), but little is known about the variation of LPS and TLR4 during the progression of NAFLD. Probiotics were able to inhibit proliferation of harmful bacteria and improve gastrointestinal barrier function. However, it's unclear whether LPS/TLR4 is involved in the protection effect of probiotics on NAFLD. In this study, we described characteristic of gut microbiota structure in the progression of NAFLD, and we also analyzed the relationship between gut microbiota and LPS/TLR4 in this process. Furthermore, we applied probiotics intervention to investigate the effect of probiotics on gut flora structure, intestinal integrity, serum LPS, liver TLR4 and liver pathology. Our results showed that serum LPS and liver TLR4 were highly increased during progression of NAFLD, with gut flora diversity and gut mircobiological colonization resistance (B/E) declining. Furthermore, probiotics could improve gut microbiota structure and liver pathology. Probiotics could also downregulate serum LPS and liver TLR4. Our results suggested that both gut flora alteration and endotoxemia may be involved in the progression of NAFLD. Probiotics may delay the progression of NAFLD via LPS/TLR4 signaling.

摘要

肠道来源的细菌脂多糖(LPS)和随后的肝脏 toll 样受体 4(TLR4)激活被认为与饮食诱导的非酒精性脂肪性肝病(NAFLD)的发病有关,但关于 LPS 和 TLR4 在 NAFLD 进展过程中的变化知之甚少。益生菌能够抑制有害细菌的增殖,改善胃肠道屏障功能。然而,目前尚不清楚 LPS/TLR4 是否参与了益生菌对 NAFLD 的保护作用。在本研究中,我们描述了 NAFLD 进展过程中肠道微生物群落结构的特征,还分析了这一过程中肠道微生物群落与 LPS/TLR4 之间的关系。此外,我们应用益生菌干预来研究益生菌对肠道菌群结构、肠道完整性、血清 LPS、肝脏 TLR4 和肝脏病理的影响。我们的结果表明,在 NAFLD 进展过程中,血清 LPS 和肝脏 TLR4 显著升高,而肠道菌群多样性和肠道微生物定植抵抗力(B/E)下降。此外,益生菌可以改善肠道菌群结构和肝脏病理。益生菌还可以下调血清 LPS 和肝脏 TLR4。我们的结果表明,肠道菌群改变和内毒素血症可能都参与了 NAFLD 的进展。益生菌可能通过 LPS/TLR4 信号通路延缓 NAFLD 的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7f02308a4ce7/srep45176-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/a69a6656ba76/srep45176-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e0d41dde4c9d/srep45176-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/79a1dd0336cb/srep45176-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/c2a1d3a73663/srep45176-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e44ab6daacbf/srep45176-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7a46e23338d5/srep45176-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/8a999fe7696e/srep45176-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7f02308a4ce7/srep45176-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/a69a6656ba76/srep45176-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e0d41dde4c9d/srep45176-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/79a1dd0336cb/srep45176-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/c2a1d3a73663/srep45176-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/e44ab6daacbf/srep45176-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/7a46e23338d5/srep45176-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/8a999fe7696e/srep45176-f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45fe/5368635/00ef569fc63f/srep45176-f9.jpg

相似文献

[1]
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.

Sci Rep. 2017-3-28

[2]
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.

Free Radic Biol Med. 2017-1

[3]
Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.

Appl Microbiol Biotechnol. 2020-6

[4]
Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.

Cell Physiol Biochem. 2018

[5]
Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?

JPEN J Parenter Enteral Nutr. 2013-3-28

[6]
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.

World J Gastroenterol. 2014-6-21

[7]
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

World J Gastroenterol. 2014-11-14

[8]
Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease.

mBio. 2020-2-4

[9]
Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

Clin Biochem. 2015-7-4

[10]
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Nutrients. 2019-11-19

引用本文的文献

[1]
Intestinal flora of hepatitis C after direct antiviral drug therapy: A review.

Medicine (Baltimore). 2025-8-1

[2]
The Role of Probiotics, Prebiotics, Synbiotics, and Postbiotics in Livestock and Poultry Gut Health: A Review.

Metabolites. 2025-7-15

[3]
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.

World J Hepatol. 2025-6-27

[4]
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome.

Int J Mol Sci. 2025-4-7

[5]
The Protective Effect of FZU501 Against Alcohol-Induced Liver Injury in Mice via Gut Microbiota-Liver Axis.

Foods. 2025-3-19

[6]
Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression.

World J Hepatol. 2025-3-27

[7]
Correlation between differences in the intestinal flora structure and Chinese medicine evidence in patients with Wilson disease-related liver fibrosis analyzed via high-throughput sequencing technology.

Biosci Microbiota Food Health. 2025

[8]
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Biomedicines. 2025-2-6

[9]
Probiotic intervention and exercise mitigate inflammation and histopathological alterations in the liver of wistar rats on a high-fat diet.

Mol Biol Rep. 2025-2-9

[10]
sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.

Microorganisms. 2024-12-3

本文引用的文献

[1]
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.

Aliment Pharmacol Ther. 2015-8-24

[2]
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.

J Clin Exp Hepatol. 2015-6

[3]
Metabolic endotoxemia with obesity: Is it real and is it relevant?

Biochimie. 2016-5

[4]
Gut Microbiota: Association with NAFLD and Metabolic Disturbances.

Biomed Res Int. 2015

[5]
Non-alcoholic fatty liver disease in 2015.

World J Hepatol. 2015-6-18

[6]
Inflammasome activation and function in liver disease.

Nat Rev Gastroenterol Hepatol. 2015-6-9

[7]
Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.

Genet Mol Res. 2015-4-10

[8]
Remifentanil Ameliorates Liver Ischemia-Reperfusion Injury Through Inhibition of Interleukin-18 Signaling.

Transplantation. 2015-10

[9]
A concise review of non-alcoholic fatty liver disease.

Atherosclerosis. 2015-1-13

[10]
Common features of the metabolic syndrome and nonalcoholic fatty liver disease.

Rev Recent Clin Trials. 2014

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索